A regional leader is the center's Pediatric Stem Cell Transplantation (SCT) program, performing around 150 transplants ...

Myriad’s MyRisk® test is the first hereditary cancer test integrated into Flatiron’s OncoEMR® ...

(NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of Dr. Amy Wechsler to its Board of ...

The lease agreement for this innovative facility is expected to be finalized within the next week, emphasizing Adia Nutrition's accelerated pace in bringing advanced treatments closer to those in need ...

The AI-powered tool does not generate responses outside of the data HealthEquity provides. HSAnswers focuses on content that helps visitors learn about a full range of CDB benefit products and ...

EXTON, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- US Digestive Health (USDH), one of the nation’s largest gastroenterology (GI) practices, today announced the addition of seven new physicians to its ...

CUPERTINO, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- ARC Fertility (ARC), a highly experienced national provider of innovative fertility, family-forming and women’s and men’s health benefits for ...

Our collaboration with Codetta Bio will enable RTI to further support our clients in advancing knowledge and addressing complex challenges to improve human health,” said Dana Hancock, senior vice ...

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and ...

“We are proud to reaffirm our commitment to New Jersey by maintaining our affordable benefit-rich PPO plans for 2025,” said Jamie Reynoso, Clover’s CEO of Medicare Advantage. “At a time when many ...

Lexogen is a leader in RNA sequencing, providing cutting-edge solutions for transcriptomics research. Their products are designed to meet the needs of the scientific community, offering end-to-end ...

_______________ 1 NeuroStar TMS results analyzed from 1,169 adolescent patients and a subset with available CGI-S data demonstrated a 78% response rate and 48% remission rate; PHQ-9 demonstrated 59.4% ...